Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is well-positioned for growth and has potential in the underserved TRD patient population. They have a leading TMS franchise and are expanding their customer base through the acquisition of Greenbrook TMS. Additionally, the company is focused on addressing the demand for non-pharmacologic treatment options in the mental health industry. However, risks such as inconsistent execution, competition, and regulatory delays should be considered.

Bears say

Neuronetics is facing a challenging market with increasing competition and potential pricing pressure as more companies enter the TMS space. Despite positive results from their Phase 3 trials for COMP360, the success and market approval of this product is not guaranteed. Additionally, the company has a history of negative cash flow and may need to raise more capital in the near future.

Neuronetics Inc (STIM) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.